Saratov JOURNAL of Medical and Scientific Research
Home

Angiogenesis inhibitor in the treatment of wet age-related macular degeneration at different choroidal neovascular membrane activity

Year: 2021, volume 17 Issue: №3 Pages: 659-662
Heading: Тhematic supplement Article type: Original article
Authors: Stepanova Yu.S., Fedotov M.V., Semyonova R.R., Batishcheva Yu.S., Gileva E.V., Rusakova N.M.
Organization: Saratov State Medical University, University Clinical Hospital №2 (Clinic of Eye Diseases)
Summary:

Purpose: comparative analysis of the effectiveness of VEGF inhibitors in the treatment of patients with neovascular age-related macular degeneration (nAMD) with different activity of choroidal neovascularization (CNV). Material and Methods. A retrospective study was carried out in 30 nAMD patients (30 eyes) with active CNV and 30 nAMD patients (30 eyes) with an inactive form of CNV. The examination included visometry, ophthalmobiomicroscopy and optical coherence tomography angiography (ОСТА) of the retina. All patients were injected intravitreally aflibercept in the amount of 2 mg. Results. Patients with active CNV as a result of treatment revealed a significant increase in visual acuity from 0.16±0.04 to 0.57±0.12, a decrease in the number of neovascular diseases, an increase in vascular density from 15.7±2.6 mirr1 to 18.9±2.5 mm1 and the perfusion density of the internal retinal capillary network from 0.37±0.06 to 49±0.06. In patients with inactive CNV, there was no positive dynamics of these indicators. Conclusion. Early diagnosis of nAMD and the timely use of VEGF inhibitors with active CNV can significantly improve the visual functions of patients.

Keywords: angio-OCT, perfusion density, vascular density, VEGF inhibitors

Bibliography:
1. Alpatov SA, Shchuko AG, Urneva EM, Malyshev VV. Age-related macular degeneration. Moscow: GEOTAR-Media, 2010; p. 35-6.
2. Astakhov YuS, Lisochkina АВ, Nechiporenko PA. Modern methods of diagnosis of the "dry" form of age-related macular degeneration. Bulletin of Ophthalmology 2010; (2): 41-7.
3. Libman ES, Tolmachev RA, Shakhova EV. Epidemiological characteristics of disability due to the main forms of maculopathy. In: Macula 2006. Rostov n/D, 2006; p. 15-22.
4. World Report on Aging and Health. Geneva: World Health Organization, 2015 [Electronic resource]. URL: https:// www.who.int/ageing/events/world-report-2015-launch/en/
5. Lim LS, Mitchell P, Seddon JM, et al. Age-related macular degeneration. Lancet 2012; 379 (9827): 1728-38. URL: https:// doi.org/10.1016/S0140-6736 (12) 60282-7.
6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration/MARINA Study Group. N Engl J Med 2006; 355 (14): 1419-31. DOI: 10.1056/NEJMoa054481.
7. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration/ANCHOR Study Group. N Engl J Med 2006; 355 (14): 1432-44. DOI: 10.1056/NEJMoa062655.
8. Heier JS, Brown DM, Chong V, et al. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology 2012; 119 (12): 2537-48.
9. Zhang K, Zhang L, Weinreb RN. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov 2012; 11 (7): 541-59.

AttachmentSize
2021_03-2_659-662.pdf513.15 KB
All articles of the authors: Batischeva Yu.S. , Fedotov M.V., Gileva E.V. , Rusakova N.M. , Semyonova R.R., Stepanova Yu.S.

No votes yet